Expression of CUG2, ßIGH3 (TGFBI), and TGF-ß in bronchoscopic biopsy specimens of lung cancer patients

Expression of CUG2, ßIGH3 (TGFBI), and TGF-ß in bronchoscopic biopsy specimens of lung cancer patients: predictive value for metastasis and differential diagnosis from other thoracic malignancies — a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN52550559

Enrollment

Registered

2026-06-11

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

This is a prospective observational diagnostic accuracy study. No intervention was administered to participants. Index test: Quantitative real-time PCR (qPCR) measurement of CUG2, ßIGH3 (TGFBI), and

histopathological diagnosis confirmed from bronchoscopic biopsy specimens. Non-randomised. Participants were assigned to study groups (primary lung cancer vs. other thoracic malignancies

metastatic vs. non-metastatic) based on histopathological diagnosis and PET/CT findings at the time of diagnostic bronchoscopy, not by randomisation.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 years or older 2. Undergoing diagnostic fiberoptic bronchoscopy (FOB) for suspected primary lung cancer or suspected thoracic involvement by an extrapulmonary malignancy 3. Histopathologically confirmed diagnosis from bronchoscopic biopsy specimen 4. Adequate RNA yield from biopsy specimen (A260/A280 ratio 1.7–2.0) 5. Written informed consent obtained prior to enrollment

Exclusion criteria

Exclusion criteria: 1. Benign histology on bronchoscopic biopsy specimen 2. Insufficient RNA yield from biopsy specimen (A260/A280 ratio outside 1.7–2.0 range) 3. Non-evaluable biomarker measurements 4. Duplicate patient records 5. Age under 18 years 6. Refusal to provide written informed consent

Countries

Türkiye

Contacts

Public ContactOnder Ozturk

dronderozturk@gmail.com+905322677973

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 29, 2026